TY - JOUR
T1 - Antiviral Treatments
AU - Ison, Michael G.
N1 - Funding Information:
Disclosure Statement: M.G. Ison has received research support, paid to Northwestern University, from Alios, Astellas, Beckman Coulter, Chimerix, Gilead, Jansen/Johnson & Johnson; he has provided compensated consultation to Celltrion, Chimerix, Farmark, Genentech/Roche, Toyama/MediVector, and Shionogi, and uncompensated consultation to BioCryst, Biota, Cellex, GlaxoSmithKlein, Romark, NexBio, Theraclone, Unither Virology, and Vertex; he is also a paid member of data and safety monitor boards related to research activity conducted by Astellas, Jansen/Vertex.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistically affect the respiratory tract. The M2 inhibitors, amantadine and rimantadine, were historically effective for the prevention and treatment of influenza A but all circulating strains are currently resistant to these drugs. Neuraminidase inhibitors are the sole approved class of antivirals to treat influenza. Ribavirin, especially when combined with intravenous antibody, reduces morbidity and mortality among immunosuppressed patients.
AB - Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistically affect the respiratory tract. The M2 inhibitors, amantadine and rimantadine, were historically effective for the prevention and treatment of influenza A but all circulating strains are currently resistant to these drugs. Neuraminidase inhibitors are the sole approved class of antivirals to treat influenza. Ribavirin, especially when combined with intravenous antibody, reduces morbidity and mortality among immunosuppressed patients.
KW - Influenza
KW - Neuraminidase inhibitor
KW - Respiratory syncytial virus (RSV)
KW - Respiratory virus
KW - Ribavirin
UR - http://www.scopus.com/inward/record.url?scp=85008215967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008215967&partnerID=8YFLogxK
U2 - 10.1016/j.ccm.2016.11.008
DO - 10.1016/j.ccm.2016.11.008
M3 - Review article
C2 - 28159156
AN - SCOPUS:85008215967
VL - 38
SP - 139
EP - 153
JO - Clinics in Chest Medicine
JF - Clinics in Chest Medicine
SN - 0272-5231
IS - 1
ER -
